For immediate release
Chicago, IL – March 29, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Visa Inc. V, Novartis AG NVS, Deere & Company DE, Airbnb, Inc. ABNB, and Edwards Lifesciences Corp. EW.
Here are the highlights from Monday’s analyst blog:
Top Stock Market Reports for Visa, Novartis and Deere & Co.
Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Visa Inc., Novartis AG and Deere & Company. These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.
You can see all today’s research reports here >>>
Shares of Visa outperformed the Zacks financial transaction services sector over the past year (+1.9% vs -28.9%). The Zacks analyst believes Visa’s numerous buyouts and alliances have paved the way for long-term growth and consistently boosted its revenue. Its investments in technology strengthen its position in the payments market. A transition of payments to digital mode is a godsend. Deployments of coronavirus vaccines and the gradual upturn in consumer confidence will continue to drive spending, in turn increasing business volumes.
With its strong cash position, it remains committed to increasing its shareholder value. The strength of its balance sheet is commendable. However, high operating costs weigh on margins. Increasing customer incentives will affect turnover. Its declining liquidity volume from Asia-Pacific is disturbing. Its volumes will probably suffer from the Russian-Ukrainian situation.
Shares of Novartis have underperformed the industry Zacks Large Cap Pharmaceuticals over the past year (-0.6% vs. +23.7%). The Zacks analyst believes the Sandoz division continues to affect overall business due to pricing pressures. The strategic review (keep the business until separation) of Sandoz is progressing and an update is expected by the end of 2022. Generic competition for key drugs and pipeline setbacks are also issues.
However, Novartis has a strong and diversified portfolio. Strong momentum from key brands such as psoriasis drug Cosentyx, cardiovascular drug Entresto, gene therapy Zolgensma, the oncology portfolio and the launch of Kesimpta continues to drive performance. The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent and expanding the label of key drugs should also boost performance. The progress of the pipeline is impressive and the company has promising candidates.
Shares of Deere outperformed the Zacks Manufacturing – Farm Equipment industry over the past year (+18.6% vs. +13.8%). The Zacks analyst believes the continued rise in commodity prices will continue to fuel demand for farm equipment, encouraging farmers to increase spending on new farm equipment.
Replacement request to upgrade old equipment will support Deere’s superior results. Demand for agricultural and construction equipment will continue to be supported by positive fundamentals, including favorable crop prices, economic growth, and increased infrastructure spending in fiscal 2022.
Deere should benefit from growth in non-residential investment and strong order activity from independent rental companies. A focus on investing in new products equipped with the latest technology will automate farming, which will drive Deere’s growth. However, higher material and labor costs are likely to reduce the margin.
Other noteworthy reports we’re featuring today include Airbnb, Inc. and Edwards Lifesciences Corp.
Why haven’t you watched Zacks best action?
Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. To visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.
The infrastructure stock boom will sweep America
A massive push to rebuild America’s crumbling infrastructure will soon be underway. It is bipartisan, urgent and inevitable. Billions will be spent. Fortunes will be made.
The only question is “Are you going to get into good stocks early when their growth potential is greatest?”
Zacks released a special report to help you do just that, and today it’s free. climb.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.